

4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 573

[Docket No. FDA-2019-F-5401]

Alzchem Trostberg GmbH; Filing of Food Additive Petition (Animal Use)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification; petition for rulemaking.

SUMMARY: The Food and Drug Administration (FDA or we) is announcing that Alzchem Trostberg GmbH has filed a petition proposing that the food additive regulations be amended to provide for the safe use of guanidinoacetic acid as a precursor of creatine in poultry feeds.

DATES: The food additive petition was filed on September 25, 2019.

ADDRESSES: For access to the docket, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts; and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Carissa Adams, Center for Veterinary Medicine, Food and Drug Administration,7519 Standish Pl., Rockville, MD 20855, 240-402-6283, Carissa.Adams@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (section 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 2309) has been filed by Alzchem Trostberg GmbH, CHEMIEPARK TROSTBERG, Dr.-Albert-Frank-Str. 32, 83308 Trostberg, Germany. The petition proposes to amend Title 21 of the Code

of Federal Regulations (CFR) in part 573 (21 CFR part 573) Food Additives Permitted in Feed

and Drinking Water of Animals to provide for the safe use of guanidinoacetic acid as a precursor

of creatine in poultry feeds.

The petitioner has claimed that this action is categorically excluded under 21 CFR

25.32(r) because it is of a type that does not individually or cumulatively have a significant effect

on the human environment. In addition, the petitioner has stated that, to their knowledge, no

extraordinary circumstances exist. If FDA determines a categorical exclusion applies, neither an

environmental assessment nor an environmental impact statement is required. If FDA

determines a categorical exclusion does not apply, we will request an environmental assessment

and make it available for public inspection.

Dated: November 25, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

[FR Doc. 2019-25904 Filed: 11/27/2019 8:45 am; Publication Date: 11/29/2019]